REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
29/06/2026
Voltar para busca
Dado oficial do USPTO
SYNGENE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: Estados Unidos
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
48
Atualização mais recente
29/06/2026
Tipo de marca
Mista
Classes Nice
35, 42
Data de depósito
16/08/2018
Data de registro
29/06/2021
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
29/06/2021
Última transação
29/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
31/08/2004
Primeiro uso no comércio
31/08/2004
Código do desenho
5
Tipo de titular
03
Localização do titular
Link Rd, Bangalore, IN
Examinador
BRACEY, KAREN
Unidade examinadora
M70
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the word "Syngene" in stylized font.
Titulares e representantes
Titulares
SYNGENE INTERNATIONAL LIMITED
Representantes
Julianne Abelman Womble Bond Dickinson (US) LLP
Classificação técnica
Classes Nice
Classe 35Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 35
Business servicesformulation of best practices for drug discoveryformulation developmentclinical supplieslarge molecule developmentantibody drug conjugates and clinical development services; consulting services in the field of medical practice management for others; business consulting and management in the field of clinical trialsproviding information management services; business consulting and management in the field of clinical trialsclinical data and regulatory submission management on behalf of medicalbiopharmaceutical and biotechnology companies to assist them with clinical researchclinical trials and applications for drug approval; regulatory submission managementassisting others in preparing and filing applications for new drugs with governmental regulatory bodies; business management consulting services in the field of pharmaceuticals drug development; none of the aforesaid services relating to gel imaging and gel analysis applications
Classe 42
Scientific research and custom synthesis; scientific and clinical research in the field of medicinepharmaceuticalnutraceuticals; scientific research and development; custom design and development of chemical reagents and biochemical assays; laboratory testing; laboratory testing services for research and development purposes; testing of pharmaceuticals; chemical engineering; drug discovery services; pharmaceutical drug development services; pharmaceutical products development; development of pharmaceutical preparations and medicines; scientific study and research in the field of reproductionhusbandrygeneral health of animal; biotechnology research for determining the neuronal survival of molecules in animal models; research and development services in the field of antibodiesantibody technology; custom design and development of chemical reagents and biochemical assays; designengineeringresearchdevelopment and testing services in the field of polymeric materialspolymer synthesismaterials customization for medicalscientifictechnological applications; toxicology services; toxicity analysis; toxicity testing for research purposes; conducting clinical trials; conducting clinical trials for scientific research for others; conducting clinical trials for pharmaceutical products; providing medical and scientific research information in the field of clinical trials; conducting early evaluations in the field of new pharmaceuticals; DNA analysis services for scientific research purposes; laboratory research in the field of gene expression; blood analysis services for scientific research purposes; analysis of human tissues for medical research; scientific services relating to the isolation and cultivation of human tissues and cells for research purposes; preparation of reports relating to scientific and technical research; analysis in the field of molecular biology; contract research services relating to molecular sciences; biological cloning services; structural and functional analysis of genomes; scientific and medical laboratory services; services of a chemical and/or biological laboratory; laboratory research services relating to pharmaceuticals; research and development and consultation related thereto in the field of antibodiesantibody technologychemistrybioinformaticsbiomedical devicesbiologicsbiotechnologybiotherapeuticsbiologybiochemical preparationscell linescheminformaticsgenetics and genetic engineeringgene expression systemsin vitro researchinhalation pharmaceuticalsmolecular sciencesmicro-organismsnutritionophthalmic preparationspharmacogeneticspharmacokineticspharmacologypharmaceuticalspolymerspeptide synthesisproteinsolid state characterization; toxicokinetic analysis and toxicology services; scientific and technological servicesscientific researchdevelopmentanalysistestingengineeringextractionsynthesispurification and production in the field of antibodiesactive pharmaceutical ingredients (API)biomoleculescell bank characterizationchiralitychromosome aberrationclinical chemistrycloning vectorcyclotidesDNAflow cytometrygas chromatography mass spectrometrygenesimmuno-pharmaceuticalsin vitro irritationlarge moleculeliquid chromatography mass spectrometrymicrobialsmonomersnanoparticlesnatural productspeptidesproteinsRNAsupercritical fluid chromatographysmall molecules and vaccines; none of the aforesaid services relating to gel imaging and gel analysis applicationsnone of the aforesaid services in the field of agriculturehorticulture and forestry
Publicações
Histórico de despachos e eventos da marca no USPTO.
48 publicações encontradas
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
02/06/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/06/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
02/06/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/06/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/06/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/06/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/06/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
29/06/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
28/05/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
27/05/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
26/05/2021
DPCC
DIVISIONAL PROCESSING COMPLETE
26/05/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
26/05/2021
IUAF
USE AMENDMENT FILED
06/05/2021
DRRR
DIVISIONAL REQUEST RECEIVED
06/05/2021
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
06/05/2021
EISU
TEAS STATEMENT OF USE RECEIVED
06/05/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/03/2021
EX1G
SOU EXTENSION 1 GRANTED
01/03/2021
EXT1
SOU EXTENSION 1 FILED
01/03/2021
EEXT
SOU TEAS EXTENSION RECEIVED
01/03/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
01/09/2020
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
23/07/2020
CHPB
POST PUBLICATION AMENDMENT - ENTERED
26/06/2020
APET
ASSIGNED TO PETITION STAFF
24/06/2020
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
02/06/2020
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
11/02/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
14/01/2020
PUBO
PUBLISHED FOR OPPOSITION
14/01/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
25/12/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/12/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/12/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/12/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/12/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/06/2019
GNRT
NON-FINAL ACTION E-MAILED
11/06/2019
CNRT
NON-FINAL ACTION WRITTEN
11/06/2019
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/06/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/06/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/06/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/06/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/12/2018
GNRT
NON-FINAL ACTION E-MAILED
06/12/2018
CNRT
NON-FINAL ACTION WRITTEN
06/12/2018
DOCK
ASSIGNED TO EXAMINER
03/12/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/08/2018
NWAP
NEW APPLICATION ENTERED
20/08/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SYNGENE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.